Tenderwize
Back to tender search

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 193 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of pharmaceutical products for the medicinal combination Lamivudin/Abacavir/Dolutegravir.
  • Open House rebate agreements under § 130c(1) SGB V.
Show full summary

This is an Open House supply arrangement by Techniker Krankenkasse for the pharmaceutical product combination Lamivudin/Abacavir/Dolutegravir (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with no individual negotiations and no exclusivity. The contract runs from 01.03.2025 to 28.02.2027 at the latest, but no contract value is provided. Participation and contract documents are only available electronically via the buyer portal, while submission is not allowed through the portal and must be made by email with qualified electronic signature or by post. The notice also states that the publication is not considered a public procurement contract under procurement law, so remedies are directed to social courts rather than procurement review bodies.

Risks

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Single lot covering Open House rebate agreements for the medicinal product combination Lamivudin/Abacavir/Dolutegravir. The scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated eligibility conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 27, 2027

Procurement Details

Publication date
20 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
42947-2025

Documents (1)

Similar tenders